Atamyo Therapeutics
Phase 1Atamyo brings to patients with musculoskeletal diseases a new generation of best-in-class gene therapies with enhanced safety and efficacy.
Founded
2019
Focus
RNA & Gene Therapy
About
Atamyo brings to patients with musculoskeletal diseases a new generation of best-in-class gene therapies with enhanced safety and efficacy.
Funding History
2Total raised: $48M
Series A$40MKurma PartnersMar 15, 2022
Seed$8MKurma PartnersSep 15, 2020
Company Info
TypePrivate
Founded2019
LocationParis, France
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile